{
    "root": "af6812a1-81c9-410f-bf97-59ebee0e6728",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Methylphenidate",
    "value": "20240329",
    "ingredients": [
        {
            "name": "METHYLPHENIDATE HYDROCHLORIDE",
            "code": "4B3SC438HI"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "DEXTROSE, UNSPECIFIED FORM",
            "code": "IY9XDZ35W2"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        }
    ],
    "indications": "methylphenidate hydrochloride extended-release capsules indicated treatment attention deficit hyperactivity disorder ( adhd ) , pediatric patients 6 12 years age [ ( 14 ) ] .",
    "contraindications": "• administer orally daily morning ( 2.2 ) . • capsules may swallowed whole opened entire contents sprinkled applesauce ( 2.2 ) . • crushed , chewed , divided ( 2.2 ) . • patients new methylphenidate : start 20 mg daily , titrating dose weekly 10-mg increments . doses 60 mg daily recommended ( 2.3 ) . • patients currently using methylphenidate hydrochloride tablets : based current dose regimen ( 2.4 ) . • switching methylphenidate products , discontinue treatment titrate methylphenidate hydrochloride extended release capsules ( 2.4 ) .",
    "warningsAndPrecautions": "•10 mg extended-release capsules ( ndc 0781-2383-01 ) white/light brown , ( imprinted “ sdz r10 ” ) supplied bottles 100 •20 mg extended-release capsules ( ndc 0781-2384-01 ) white , ( imprinted “ sdz r20 ” ) supplied bottles 100 •30 mg extended-release capsules ( ndc 0781-2385-01 ) yellow , ( imprinted “ sdz r30 ” ) supplied bottles 100 •40 mg extended-release capsules ( ndc 0781-2386-01 ) light brown , ( imprinted “ sdz r40 ” ) supplied bottles 100 store 20°c 25°c ( 68°f 77°f ) ; excursions permitted 15°c 30°c ( 59°f 86°f ) [ usp controlled room temperature ] . dispense tight container ( usp ) .",
    "adverseReactions": "•hypersensitivity methylphenidate components methylphenidate hydrochloride extended-release capsules . hypersensitivity , angioedema anaphylactic , reported patients treated methylphenidate [ ( 6.1 ) ] . •concomitant treatment monoamine oxidase inhibitors ( maois ) , within 14 days following discontinuation treatment maoi , risk hypertensive crises [ ( 7.1 ) ] .",
    "indications_original": "Methylphenidate hydrochloride extended-release capsules are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD), in pediatric patients 6 to 12 years of age [see Clinical Studies (14)].",
    "contraindications_original": "• Administer orally once daily in the morning ( 2.2 ). • Capsules may be swallowed whole or opened and the entire contents sprinkled on applesauce ( 2.2 ). • Should not be crushed, chewed, or divided ( 2.2 ). • Patients new to methylphenidate: Start at 20 mg daily, titrating the dose weekly in 10-mg increments. Doses above 60 mg daily are not recommended ( 2.3 ). • For patients currently using methylphenidate hydrochloride tablets: Dosage is based on current dose regimen ( 2.4 ). • If switching from other methylphenidate products, discontinue treatment and titrate with methylphenidate hydrochloride extended release capsules ( 2.4 ).",
    "warningsAndPrecautions_original": "•10 mg extended-release capsules (NDC 0781-2383-01) white/light brown, (imprinted “SDZ R10”) supplied in bottles of 100\n                     \n                        •20 mg extended-release capsules (NDC 0781-2384-01) white, (imprinted “SDZ R20”) supplied in bottles of 100\n                     \n                        •30 mg extended-release capsules (NDC 0781-2385-01) yellow, (imprinted “SDZ R30”) supplied in bottles of 100\n                     \n                        •40 mg extended-release capsules (NDC 0781-2386-01) light brown, (imprinted “SDZ R40”) supplied in bottles of 100\n                  \n                  Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [See USP controlled room temperature].\n                  Dispense in tight container (USP).",
    "adverseReactions_original": "•Hypersensitivity to methylphenidate or other components of methylphenidate hydrochloride extended-release capsules. Hypersensitivity reactions, such as angioedema and anaphylactic reactions, have been reported in patients treated with methylphenidate [see Adverse Reactions (6.1)]. \n                     \n                        •Concomitant treatment with monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOI, because of the risk of hypertensive crises [see Drug Interactions (7.1)]."
}